SPECTROSWISS SARL

Their core work

SpectroSwiss is a Lausanne-based technology SME that develops advanced mass spectrometry instruments and data processing tools. They specialize in pushing the boundaries of mass spectrometry precision — from signal processing algorithms to hardware — enabling applications in life sciences, biotherapeutics, and diagnostics. Their work spans the full chain from fundamental measurement science to application-ready tools for antibody profiling, breath-based diagnostics, and single-cell proteomics. The company has strong roots in ERC-funded research, translating proof-of-concept breakthroughs into commercial instrumentation.

What they specialise in

How they've shifted over time

In their early H2020 phase (2015-2018), SpectroSwiss focused on the foundational science: improving signal processing and measurement precision in mass spectrometry through two ERC Proof-of-Concept projects (Time2Life, Precision4Life). From 2019 onward, the company pivoted sharply toward high-impact applications — antibody profiling for immunotherapy (TopSpec), biotherapeutic data tools (A2MStools), and a major breath diagnostics platform for pathogen detection (ARIADNE). The trajectory is clear: from building better instruments to deploying them in biomedical and diagnostic contexts where precision mass spectrometry can transform clinical practice.

SpectroSwiss is moving from instrument science toward clinical and diagnostic deployment, particularly in real-time pathogen detection and biotherapeutic quality control — expect future projects at the mass-spec/diagnostics intersection.

How they like to work

SpectroSwiss frequently leads projects (3 of 5 as coordinator), indicating a company that defines research agendas rather than simply contributing components. Their coordinator projects tend to be smaller ERC-POC grants, while their participant roles are in larger collaborative efforts (TopSpec, ARIADNE) where they contribute specialist mass spectrometry capability. With 13 unique partners across 7 countries, they maintain a diverse but not sprawling network — typical of a focused technology SME that partners strategically rather than broadly.

SpectroSwiss has collaborated with 13 distinct partners across 7 countries, reflecting a solid European network for an SME of their size. Their partnerships span academia and industry, centered on life science and analytical chemistry communities.

What sets them apart

SpectroSwiss occupies a rare niche: a commercial SME with deep roots in ERC-level fundamental research, translating proof-of-concept mass spectrometry breakthroughs directly into usable tools and instruments. Unlike large instrument manufacturers, they are agile enough to tackle frontier applications like breath-based virus detection and single-cell proteomics. Their Lausanne base places them in one of Europe's strongest life science ecosystems (EPFL, CHUV, BioPôle), giving consortium builders access to both Swiss precision engineering and a rich local innovation network.

Highlights from their portfolio

• ARIADNE
  Largest project by funding (EUR 450K), running until 2026, tackling the ambitious goal of real-time noninvasive breath analysis for detecting intact viruses and bacteria.
• TopSpec
  Moved SpectroSwiss into the biotherapeutics space with next-generation antibody profiling — a commercially significant application area with strong pharma demand.
• Time2Life
  Their first H2020 project and an ERC Proof-of-Concept grant, marking the transition from academic research into a commercial technology company.